<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758325</url>
  </required_header>
  <id_info>
    <org_study_id>TMO1902</org_study_id>
    <nct_id>NCT04758325</nct_id>
  </id_info>
  <brief_title>The Sarcoma Biology and Outcome Project</brief_title>
  <acronym>SarcBOP</acronym>
  <official_title>A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients With Soft-tissue and Bone Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Richard F Schlenk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SarcBOP - An interdisciplinary and translational registry&#xD;
&#xD;
      SarcBOP aims to establish a database that integrates every aspect possibly relevant to&#xD;
      sarcoma treatment and research. SarcBOP thus will not be limited to specific questions or&#xD;
      patient groups, but instead will build a comprehensive database including clinical,&#xD;
      pathologic, and radiologic information, multi-layered molecular data, and patient-reported&#xD;
      outcomes, combined with a dedicated biobank for tissue samples and liquid biopsies. As the&#xD;
      study integrates seamlessly with the clinical activities of the Heidelberg Sarcoma Center,&#xD;
      the Molecular Diagnostics Program of NCT Heidelberg, including the NCT/DKTK MASTER Program,&#xD;
      and with the NCT Trial Center, including the PMO Clinical Trials Program, SarcBOP will&#xD;
      generate a comprehensive and continuously growing resource for clinicians, researchers, and,&#xD;
      finally, patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following data are collected and stored:&#xD;
&#xD;
        -  Demographics&#xD;
&#xD;
        -  Comorbidities&#xD;
&#xD;
        -  Clinical characteristics at diagnosis, relapse and progression&#xD;
&#xD;
        -  Radiologic images&#xD;
&#xD;
        -  Histological images&#xD;
&#xD;
        -  Treatments including DRG and OPS data, including detailed information on surgical,&#xD;
           radiation, and medical therapy as well as treatment relevant follow-up data&#xD;
&#xD;
        -  Longitudinal disease assessments&#xD;
&#xD;
        -  Clinical outcome&#xD;
&#xD;
        -  Genomic, transcriptomic, epigenomic and proteomic data&#xD;
&#xD;
        -  Patient reported outcomes&#xD;
&#xD;
      Furthermore, biological samples are collected and processed by the Sample Processing&#xD;
      Laboratory of the Heidelberg Center for Personalized Oncology and the NCT Biobank.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2032</completion_date>
  <primary_completion_date type="Anticipated">July 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The length of time from the date of diagnosis disease, that patients diagnosed with are still alive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>The length of time from the date of diagnosis disease, that patients diagnosed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>length of time during and after treatment, that a Patient lives with the disease without getting worse</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Core questionnaire QLQ-C30</measure>
    <time_frame>5 years</time_frame>
    <description>Standardized Quality of Life Assessment, Higher values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>Fatigue module QLQ-FA12</measure>
    <time_frame>5 years</time_frame>
    <description>Standardized Quality of Fatigue, Higher values are worse</description>
  </other_outcome>
  <other_outcome>
    <measure>PHQ-4 (anxiety and depression)</measure>
    <time_frame>5 years</time_frame>
    <description>Standardized Quality of anxiety and depression, Higher values are worse</description>
  </other_outcome>
  <other_outcome>
    <measure>FACT-cog (cognitive function)</measure>
    <time_frame>5 years</time_frame>
    <description>Standardized Quality of cognitive function, Higher values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>DASH</measure>
    <time_frame>5 years</time_frame>
    <description>Disability of the arm, shoulder and hand, lower values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>EFAS</measure>
    <time_frame>5 years</time_frame>
    <description>European foot and ankle society, higher values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>OKS</measure>
    <time_frame>5 years</time_frame>
    <description>Oxford knee score function and pain questionnaire after total knee replacement surgery, (TKR), higher values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>MSTS</measure>
    <time_frame>5 Years</time_frame>
    <description>Musculoskeletal tumor society score, higher values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>ODI</measure>
    <time_frame>5 Years</time_frame>
    <description>Oswestry back pain disability questionnaire after spinal surgery, lower values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>OHS</measure>
    <time_frame>5 years</time_frame>
    <description>Oxford hip score - Function and pain questionnaire after hip replacement surgery, higher values are better</description>
  </other_outcome>
  <other_outcome>
    <measure>PSQI</measure>
    <time_frame>5 years</time_frame>
    <description>Pittsburgh Sleep Quality Index, Higher values are worse</description>
  </other_outcome>
  <other_outcome>
    <measure>Sociodemographics</measure>
    <time_frame>Baseline only</time_frame>
    <description>Sociodemographic data</description>
  </other_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Sarcoma</condition>
  <condition>Malignant Mesenchymoma</condition>
  <condition>Sarcoma of Bone and Connective Tissue</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Soft-tissue and Bone Sarcoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Ability to understand nature and individual consequences of the registry&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Subjects who are physically or mentally capable of giving consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Severe neurological or psychiatric disorder interfering with the ability to give written&#xD;
        informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard F. Schlenk, Prof.Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Tumour Disease</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph E. Heilig, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>National Center for Tumour Disease</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Fröhling, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>National Center for Tumour Disease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard F. Schlenk, Prof.Dr.med</last_name>
    <phone>+49 6221 56 6228</phone>
    <email>richard.schlenk@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SarcBOP Team</last_name>
    <email>sarcbop@nct-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Tumour Diseases, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Editha Gnutzmann, M.A.</last_name>
      <phone>+49 6221 5636235</phone>
      <email>editha.gnutzmann@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>SarcBOP Team</last_name>
      <email>sarcbop@nct-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nct-heidelberg.de/sarcbop</url>
    <description>official website of SarcBOP</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Richard F Schlenk</investigator_full_name>
    <investigator_title>Head of NCT trials center and Clinical Trials</investigator_title>
  </responsible_party>
  <keyword>rare disease</keyword>
  <keyword>database</keyword>
  <keyword>treatment</keyword>
  <keyword>research</keyword>
  <keyword>molecular diagnostic</keyword>
  <keyword>translational approach</keyword>
  <keyword>interdisciplinary approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Mesenchymoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

